Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Blood

Volumn 118, Issue 13, 2011, Pages 3489-3498

  Badoux, Xavier C ^a   Keating, Michael J ^a   Wen, Sijin ^b   Lee, Bang Ning ^b   Sivina, Mariela ^a   Reuben, James ^b   Wierda, William G ^a   O'Brien, Susan M ^a   Faderl, Stefan ^a   Kornblau, Steven M ^a   Burger, Jan A ^a   Ferrajoli, Alessandra ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; LENALIDOMIDE;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GERIATRIC DISORDER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80053350801     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-339077     Document Type: Article

References (45)

1. National Cancer Institute. Median Age of Cancer Patients at Diagnosis by Primary Cancer Site, Race and Sex, 2003-2007. Bethesda, MD: National Cancer Institute; 2010.
2. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-3391.
3. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
5. Ferrajoli A, O'Brien S, Wierda WG, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005;46:48.
6. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(4):498-503.
7. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109(11):2291-2298. (Pubitemid 46801560)
8. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(2):171-178.
9. Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187-197.
10. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343-5349. (Pubitemid 46623164)
11. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291-5297.
12. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-386. (Pubitemid 29295864)
13. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
14. Gao H, Ferrajoli A, Cohen EN, et al. Treatment with lenalidomide has a positive immunomodulatory effect in patients with chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11): Abstract 2107.
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
16. Rassenti LZ, Kohsaka H, Kipps TJ. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995; 764:463-473. (Pubitemid 26136202)
17. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901. (Pubitemid 39096916)
18. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205. (Pubitemid 46638957)
19. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
20. Charlson ME, Pompei P, Ales K, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383. (Pubitemid 17055592)
21. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2010;117(2):563-574.
22. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050- 3058.
23. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011;117(5):1662-1669.
24. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230-239. (Pubitemid 47069536)
25. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757.
26. Robak T, Blasinska-Morawiec M, Blonski JZ, Dmoszynska A. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1999;34(1):151-157. (Pubitemid 29248670)
27. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384.
28. Mateos M-V, Garcia-Sanz R, Colado E, et al. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol. 2008;140(3):324-326.
29. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117(10):2127-2135.
30. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(13):1175-1181.
31. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437. (Pubitemid 351949771)
32. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinasedependent pathway. Blood. 2010;115(13):2619-2629.
33. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787-1790. (Pubitemid 38268973)
34. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94(9):1266-1273.
35. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650-4657.
36. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57(12):1849-1859.
37. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128(2):192-203.
38. Lee B-N, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia Cancer. 2011;117(17): 3999-4008.
39. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
40. Hoellenriegel J, Meadows SA, Wierda WG, Keating MJ, Lannutti B, Burger JA. Phosphoinositide 3 -kinase (PI3K) delta inhibition with CAL-101 blocks B-cell receptor (BCR) signaling andthe prosurvival actions of nurselike cells (NLC), inchronic lymphocytic leukemia [abstract]. Blood(ASH Annual Meeting Abstracts). 2010;116(21):48.
41. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 abrogates BCR- and nurse-like cell-derived activation of CLL cells in vitro and in vivo [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):45.
42. Ferrajoli A, Badoux X, O'Brien S, et al. The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1395.
43. Coleman M, Martin P, Ruan J, et al. The THRIL (thalidomide [Th], rituximab [R], and lenalidomide [L]) regimen for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma: daily alternating IMiDs and rituximab maintenance. ASCO Meeting Abstracts. 2008; 26(15 suppl):7079.
44. Egle A, Steurer M, Melchardt T, Stoll M, Greil R. The REVLIRIT CLL5 AGMT Study: a phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated chronic lymphocytic leukemia (CLL). Results of a Planned Interim Analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3453.
45. James DF, Brown JR, Werner L, et al. Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: report of an ongoing study [abstract]. ASCO Meeting Abstracts. 2010;28(15 suppl):6583.